Search results
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
Zacks via Yahoo Finance· 3 hours agoThe drug has seen a solid uptake since its approval, given the market opportunity. The label...
Zenas adds $200M series C to reach a bucket of key readouts for its lead monoclonal antibody
FierceBiotech· 2 hours agoZenas BioPharma has bagged a $200 million series C, extending its cash runway another 18 months...
...Publication of "Sigyn Therapy, an Emerging Candidate to Address Endotoxemia, Sepsis, and Drug...
NewMediaWire via Yahoo Finance· 2 hours agoSAN DIEGO, CA - (NewMediaWire) - May 07, 2024 - Sigyn Therapeutics, Inc. ("Sigyn Therapeutics",...
BioInvent International AB: Interim Report January-March 2024
Digital Journal· 2 weeks ago...clinical trial collaboration and supply agreement signed with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab) (R)= Regulatory event FINANCIAL INFORMATION...stage biotech company that discovers and develops novel and first-in-class...
Baird starts Spyre stock coverage with outperform rating By Investing.com
Investing.com· 5 days agoThe coverage by Baird is optimistic about Spyre's potential to impact the inflammatory bowel disease...
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference
KAMR Amarillo· 2 hours agoElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors ...
Adcentrx Therapeutics Announces China NMPA Grants IND Clearance for ADRX-0706, a Novel Nectin-4 ADC...
NBC 17 Raleigh· 13 hours ago...patient enrollment into the Phase 1a/1b studySAN DIEGO and SHANGHAI, May 6, 2024 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, announced today that China...
2024 ASCO | Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor
FOX 59 Indianapolis· 2 weeks ago...USA, from May 31-June 4, 2024. 9MW2821 is the first site-specific conjugated novel ADC targeting...
Q1 2024 BioNTech SE Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 4 hours agoWe believe our cancer vaccine candidates are particularly suited for early intervention, while thoughtfully designed combination treatments are intended for advanced and high-volume ...
...Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics...
WFRV 5 Green Bay· 5 days agoTarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile. Novel small molecules and protein ...
